Training in Translational ADRD Neuroscience (TITAN)

项目总结/摘要 人口老龄化导致越来越多的老年痴呆症患者面临公共卫生危机 疾病（AD）和相关痴呆（ADRD）。自FDA上次批准以来， ADRD的新疗法继续在过去十年中在了解ADRD方面取得的巨大进展 病理生理学，我们将需要重要的临床前和临床转化研究，使候选人 治疗临床使用，并发展足以遏制公共卫生影响的治疗设备， ADRD。这一成功的关键将是新一代的ADRD科学家，特别是科学家， 设计和执行翻译研究所需的独特培训和技能。这种培训很少提供 通过传统的医学、临床心理学、基础科学或生物统计学教育课程。作为 因此，缺乏训练有素的ADRD翻译研究人员。此外，多样性不足 在目前活跃的ADRD翻译研究者中，限制了独特的视角和团队 科学的协同作用，可以推动该领域的关键解决方案。 我们在这里提出了一个新的培训计划，在翻译ADRD研究题为“培训翻译ADRD 神经科学（泰坦）”在加州大学欧文分校（UCI）。新的培训计划将广泛 包括有前途的研究生和初级翻译科学家，如医生，临床 心理学家、流行病学家、生物统计学家、生物伦理学家和神经科学家。我们制定了一份 优秀的和同样多样化的导师团队谁将确保这一新的培训计划的成功。 该计划将在ADRD转化研究中开发新的培训机会，同时还利用 UCI拥有大量的科学和培训资源，包括NIA P30资助的阿尔茨海默病 研究中心（ADRC），自2020年4月以来，包括一个研究教育部分， 互补的目标。同样，UCI临床和转化科学研究所（ICTS）是UCI的 NCATS资助的CTSA计划，提供协同培训选项，如K俱乐部， 负责任地举办研究讲习班和KL 2资助机制。我们将招募来自世界各地的 多学科专业以及来自全国代表性不足的种族和族裔群体的个人， 残疾人、来自弱势背景的人和妇女。

Project Summary/Abstract Population aging is leading to a public health crisis in the growing number of people affected by Alzheimer’s disease (AD) and Related Dementias (ADRD). It has been more than 15 years since the last FDA approval for a new treatment for ADRD. To continue the dramatic progress over the last decade in understanding ADRD pathophysiology we will require significant preclinical and clinical translational research to bring candidate therapies to clinical use and grow a therapeutic armamentarium sufficient to curb the public health impact of ADRD. Essential to this success will be a new generation of ADRD scientists, especially scientists with the unique training and skills necessary to design and perform translational research. This training is rarely provided through the traditional course of medical, clinical psychology, basic science, or biostatistical education. As a result, there is a dearth of well-trained ADRD translational investigators. Moreover, there is inadequate diversity among the current group of active ADRD translational investigators, limiting the unique perspectives and team science synergies that could propel the field toward critical solutions. We propose here a new training program in translational ADRD research titled “Training in Translational ADRD Neuroscience (TITAN)” at the University of California, Irvine (UCI). This new training program will be broadly inclusive of promising graduate students and junior translational scientists, such as medical doctors, clinical psychologists, epidemiologists, biostatisticians, bioethicists, and neuroscientists. We have assembled an outstanding and similarly diverse team of preceptors who will ensure the success of this new training program. The program will develop novel training opportunities in ADRD translational research while also leveraging the considerable scientific and training resources at UCI, including the NIA P30-funded Alzheimer’s Disease Research Center (ADRC), which since April 2020 includes a Research Education Component with complementary objectives. Similarly, the UCI Institute for Clinical and Translational Science (ICTS) is UCI’s NCATS-funded CTSA program that offers synergistic training options to be leveraged, such as the K-club, responsible conduct of research workshops, and KL2 funding mechanisms. We will recruit diverse trainees from multidisciplinary specialties as well as individuals from nationally underrepresented racial and ethnic groups, individuals with disabilities, individuals from disadvantaged backgrounds, and women.